Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

A Genomic Approach in High-Grade B Cell Lymphoma with MYC and BCL2 and / or BCL6 Rearrangements: Two Clusters Stood out on Next Generation Sequencing Results

Arsène Vacherot, Emmanuel Beillard, Catherine Chassagne-Clément, Marie-Charlotte Laude, Pierre Sesques, Laure Lebras, Alexandra Traverse-Glehen, Claire Mauduit, Mauricette Michallet, Stéphane Morisset, Anne-Sophie Michallet, Yann Guillermin

Blood (2022) 140 (Supplement 1): 11878–11879.

https://doi.org/10.1182/blood-2022-169510

Published: 2022

Journal Articles

Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas

Blood (2021) 138 (Supplement 1): 809.

https://doi.org/10.1182/blood-2021-150034

Published: 2021

Journal Articles

Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma

Blood (2020) 136 (Supplement 1): 43–45.

https://doi.org/10.1182/blood-2020-138789

Published: 2020

Journal Articles

Retrospective Evaluation of Rituximab, Methotrexate, Procabazine, Vincristine and Etoposide Followed By Consolidation with Rituximab, Aracytine and Ifosfamide for Elderly Patients with Newly Diagnosed Primary CNS Lymphoma

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-139946

Published: 2020

Journal Articles

Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL

Blood (2020) 135 (5): 360–370.

https://doi.org/10.1182/blood.2019001904

Published: 2020

Includes: Supplemental data

Journal Articles

Follicular Lymphoma Grade 3A Exhibits Pathological and Cytogenetic Diversity, but Similar Prognosis Compared to FL Grade 1-2: Pooled Analysis of 1757 Follicular Lymphomas from the PRIMA and Relevance Trials

Camille Laurent, MD PhD, Danielle Canioni, MD, Bettina Fabiani, MD, Véronique Meignin, Catherine Chassagne-Clément, MD, Peggy Dartigues-Cuillères, MD, Christiane Copie, MDPhD, Guillaume Cartron, Franck Morschhauser, MD, Gilles Salles, MD PhD, Luc Xerri, MD PhD

Blood (2018) 132 (Supplement 1): 778.

https://doi.org/10.1182/blood-2018-99-115831

Published: 2018

Journal Articles

HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization

Christophe Boudesco, Els Verhoeyen, Laurent Martin, Catherine Chassagne-Clement, Leila Salmi, Rana Mhaidly, Céline Pangault, Thierry Fest, Selim Ramla, Fabrice Jardin, Olaf-Oliver Wolz, Alexander N. R. Weber, Carmen Garrido, Gaetan Jego

Blood (2018) 132 (5): 510–520.

https://doi.org/10.1182/blood-2017-12-819706

Published: 2018

Includes: Supplemental data

Journal Articles

Sequential Lymphoma between Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma: Clinicopathological Characteristics and Outcome of 18 Patients from Lysa Center

Guillaume Aussedat, Hervé Ghesquières, MD PhD, Aspasia Stamatoullas, MD, Pierre Hirsch, MDPhD, Emmanuelle Nicolas-Virelizier, MD, Guillaume Cartron, Caroline Regny, Lionel Karlin, MD, Catherine Chassagne-Clément, MD, Violaine Safar, Nicolas Albin, MD, Antoine Deleuze, Alexis Lambour, Nicolas Daguindau, Christiane Copie, MDPhD, Richard Lemal, MD, Gilles Salles, MD PhD, Alexandra traverse-Glehen, MD PhD, Clementine Sarkozy, MD

Blood (2017) 130 (Supplement 1): 4149.

https://doi.org/10.1182/blood.V130.Suppl_1.4149.4149

Published: 2017

Journal Articles

Prognostic Value of P53 and Myc Protein Expression in Follicular Lymphomas in the PRIMA Trial in the Lysa Group

Danielle Canioni, MD, Laure Joseph, MD, Bettina Fabiani, MD, Catherine Chassagne-Clément, MD, Peggy Dartigues-Cuillères, MD, Frederic Charlotte, MD, Pauline Brice, MD, Pierre Feugier, MD, Franck Morschhauser, MD PhD, Anne Sonet, MD, Gilles Salles, MD PhD, Luc Xerri, MD PhD

Blood (2017) 130 (Supplement 1): 1508.

https://doi.org/10.1182/blood.V130.Suppl_1.1508.1508

Published: 2017

Journal Articles

Combination of Rituximab with Chemotherapy Improved Outcome of Newly Diagnosed Primary CNS Lymphoma: A Retrospective Study of 209 Unselected Patients Referred to a Single Institution

Herve Ghesquieres, MD PhD, Celine Segura-Ferlay, MS, Gaelle Fossard, MD, Francois Ducray, MD PhD, Violaine Safar, MD, Philippe Rey, MD, Emmanuelle Nicolas-Virelizier, MD, Catherine Sebban, MD, Amine Belhabri, MD, Pierre Biron, MD, Emmanuel Jouanneau, MD PhD, David Meyronnet, MD PhD, Catherine Chassagne-Clement, MD, Jerome Honnorat, MD PhD, Jean-Yves Blay, MD PhD

Blood (2015) 126 (23): 1544.

https://doi.org/10.1182/blood.V126.23.1544.1544

Published: 2015

Journal Articles

A New Prognostic Score for Patients Older Than 60 Years with a Classical Hodgkin Lymphoma: A Retrospective Analysis on 165 Patients

Violaine Safar, MD, Nadia Oussaid, Alexandra Traverse-Glehen, MD PhD, Catherine Chassagne-Clement, MD, Catherine Sebban, MD, Anne-Sophie Michallet, MD PhD, Pierre Biron, MD, Emmanuel Bachy, MDPhD, Emmanuelle Nicolas-Virelizier, MD, Francoise Berger, MDPhD, Bertrand Coiffier, MD PhD, Gilles Salles, MDPhD, Herve Ghesquieres, MDPhD

Blood (2014) 124 (21): 1721.

https://doi.org/10.1182/blood.V124.21.1721.1721

Published: 2014

Journal Articles

Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era

Blood (2014) 124 (21): 1664.

https://doi.org/10.1182/blood.V124.21.1664.1664

Published: 2014

Journal Articles

Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma

Clémentine Sarkozy, John Francis Seymour, Christophe Ferme, Dolores Caballero, Hervé Ghesquieres, Sirpa Leppa, Richard Delarue, Lars Moller Pedersen, Christiane Mounier, Maria Gomes Da Silva, Catherine Chassagne-Clement, Marie Maerevoet, Gilles Salles

Blood (2014) 123 (17): 2740–2742.

https://doi.org/10.1182/blood-2014-02-553693

Published: 2014

Journal Articles

Utility Of Post Therapy Brain Surveillance Imaging In The Detection Of Primary CNS Lymphoma (PCNSL) Relapse

Gaelle Fossard, MD, Emmanuelle Nicolas-Virelizier, MD, Philippe Rey, MD, Francois Ducray, MD, Emmanuel Jouanneau, MD, PhD, Pierre Faurie, MD, Amine Belhabri, MD, Marie Pierre Sunyach, MD, Catherine Chassagne-Clement, MD, Philippe Thiesse, MD, Catherine Sebban, MD, Pierre Biron, MD, Jean-Yves Blay, MD, PhD, Herve Ghesquieres, MD, PhD

Blood (2013) 122 (21): 933.

https://doi.org/10.1182/blood.V122.21.933.933

Published: 2013

Journal Articles

Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase

Clémence Roux, Franck-Emmanuel Nicolini, Delphine Rea, Mathilde Niault, Luigina Mollica, Françoise Berger, Catherine Chassagne-Clément, Isabelle Tigaud, Michel Tulliez, Stéphane Giraudier, Ali Turhan, Philippe Rousselot, Laurence Legros

Blood (2013) 122 (17): 3082–3084.

https://doi.org/10.1182/blood-2013-07-513879

Published: 2013

Journal Articles

Treatment of Primary CNS Lymphoma in the Elderly with High-Dose Methotrexate Containing Chemotherapy Followed Radiotherapy or Chemotherapy Alone Plus Deferred Radiotherapy: Evaluation of Modification of Treatment Modalities in Leon Berard Cancer Center.

Hervé Ghesquières, MD, Agathe Bajard, Gilles Albrand, MD, Khaoula Alaoui-Slimani, MD, Philippe Rey, MD, Catherine Sebban, MD, Marie Pierre Sunyack, MD, Emmanuel Jouanneau, MD, PhD, Francois Ducray, MD, Catherine Chassagne-Clement, MD, Pierre Biron, MD, Jean-Yves Blay, MD, PhD

Blood (2009) 114 (22): 2702.

https://doi.org/10.1182/blood.V114.22.2702.2702

Published: 2009

Journal Articles

Farnesyltransferase Inhibitor Tipifarnib (Zarnestra) in Refractory Mantle Cell Lymphoma (MCL): A Therapeutic Target Only for Specific Patients Categorized by the 2-Gene Classifier for Predictive Response to Tipifarnib.

Delphine Rolland, Vincent Ribrag, Corinne Haioun, Herve Ghesquieres, MD, Fabrice Jardin, Reda Bouabdallah, Patricia Franchi, Josette Briere, Eric De Kerviler, Catherine Chassagne-Clement, Mitch Raponi, PhD, Remi Houlgatte, Jean-Philippe Jais, Catherine Thieblemont

Blood (2008) 112 (11): 1561.

https://doi.org/10.1182/blood.V112.11.1561.1561

Published: 2008

NARROW

A Genomic Approach in High-Grade B Cell Lymphoma with MYC and BCL2 and / or BCL6 Rearrangements: Two Clusters Stood out on Next Generation Sequencing Results

Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas

Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma

Retrospective Evaluation of Rituximab, Methotrexate, Procabazine, Vincristine and Etoposide Followed By Consolidation with Rituximab, Aracytine and Ifosfamide for Elderly Patients with Newly Diagnosed Primary CNS Lymphoma

Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL

Follicular Lymphoma Grade 3A Exhibits Pathological and Cytogenetic Diversity, but Similar Prognosis Compared to FL Grade 1-2: Pooled Analysis of 1757 Follicular Lymphomas from the PRIMA and Relevance Trials

HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization

Sequential Lymphoma between Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma: Clinicopathological Characteristics and Outcome of 18 Patients from Lysa Center

Prognostic Value of P53 and Myc Protein Expression in Follicular Lymphomas in the PRIMA Trial in the Lysa Group

Combination of Rituximab with Chemotherapy Improved Outcome of Newly Diagnosed Primary CNS Lymphoma: A Retrospective Study of 209 Unselected Patients Referred to a Single Institution

A New Prognostic Score for Patients Older Than 60 Years with a Classical Hodgkin Lymphoma: A Retrospective Analysis on 165 Patients

Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era

Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma

Utility Of Post Therapy Brain Surveillance Imaging In The Detection Of Primary CNS Lymphoma (PCNSL) Relapse

Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase

Treatment of Primary CNS Lymphoma in the Elderly with High-Dose Methotrexate Containing Chemotherapy Followed Radiotherapy or Chemotherapy Alone Plus Deferred Radiotherapy: Evaluation of Modification of Treatment Modalities in Leon Berard Cancer Center.

Farnesyltransferase Inhibitor Tipifarnib (Zarnestra) in Refractory Mantle Cell Lymphoma (MCL): A Therapeutic Target Only for Specific Patients Categorized by the 2-Gene Classifier for Predictive Response to Tipifarnib.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only